S. Verma reports holding a Tier 1 Canada Research Chair in Cardiovascular Surgery and receiving grants, research support, and speaking honoraria from and acting as an advisor for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, the Canadian Heart Research Centre, the Canadian Medical and Surgical Knowledge Translation Research Group, Eli Lilly, HLS Therapeutics, Humber River Health, Janssen, Merck, Novartis, Novo Nordisk, Pfizer, PhaseBio, S & L Solutions Event Management, Inc, Sanofi, and Sun Pharma. M. Böttcher reports advisory board participation for AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Novo Nordisk, and Sanofi. D. Dicker reports having received research grants from Boehringer Ingelheim, Eli Lilly, Graviton, and Novo Nordisk; payment or honoraria for speaker/advisory boards from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Hoffman-La Roche, and Novo Nordisk; support for attending meetings and travel from Boehringer Ingelheim, Eli Lilly, and Novo Nordisk; and unpaid executive committee roles for the European Federation of Internal Medicine and the European Association for the Study of Obesity. D. Rubino reports research grants and consulting fees from Amgen, AstraZeneca, Boehringer Ingelheim, Cytoki Pharma, Eli Lilly, Kallyope, Neurocrine Biosciences, Inc, Nod Thera, Novo Nordisk, Pfizer, Regeneron Pharmaceuticals, Inc, Shionogi, Inc, and Terns Pharmaceuticals. P. Sbraccia received payment of honoraria from Amryt Pharma (Chiesi), Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Pfizer, and Roche, and as a member of advisory boards and payment of honoraria for lectures from Amryt Pharma (Chiesi), Eli Lilly and Novo Nordisk. A.M. Sharma received honoraria for consulting and speaking from AbbVie, Allurion, Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, and Oviva. W.T. Garvey has been a consultant on advisory boards for AbbVie, Allurion, Alnylam Pharmaceuticals, Boehringer Ingelheim, Carmot/Roche, Corcept, Eli Lilly, Fractyl Health, Gan & Lee, Inogen, Keros Therapeutics, MetSera, Neurocrine, Novo Nordisk, Pfizer, Regeneron, Terns Pharmaceuticals, and Zealand. He has also served as a site principal investigator for multicentered clinical trials sponsored by his university and funded by Carmot/Roche, Eli Lilly, Epitomee, Neurovalens, Novo Nordisk, Terns Pharmaceuticals, Viking Therapeutics, and Zealand. P. Brown, L. Smedegaard, and R. Sørrig are employees and shareholders with Novo Nordisk A/S.
PubMed
